| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC | Director | Option to purchase Ordinary Shares | 710,711 | 01 Jul 2022 | Direct | ||
| LAVA Therapeutics NV | Director | Common Shares (Right to Buy) | 33,390 | 13 Feb 2025 | Direct | ||
| GW PHARMACEUTICALS PLC | Director | Ordinary Shares | 0 | 05 May 2021 | Direct | ||
| GW PHARMACEUTICALS PLC | Director | Share Options | 0 | 05 May 2021 | Direct | ||
| LAVA Therapeutics NV | Director | Share Options (Right to Buy) | 0 | 13 Nov 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LVTX | LAVA Therapeutics NV | 13 Nov 2025 | 1 | $0 | 4 | Director | 17 Nov 2025, 16:30 |
| LVTX | LAVA Therapeutics NV | 13 Feb 2025 | 1 | $0 | 4 | Director | 18 Feb 2025, 20:15 |
| LVTX | LAVA Therapeutics NV | 01 Jan 2025 | 0 | $0 | 3 | Director | 02 Jan 2025, 09:31 |
| ADAP | Adaptimmune Therapeutics PLC | 01 Jul 2022 | 1 | $0 | 4 | Director | 01 Jul 2022, 17:02 |
| ADAP | Adaptimmune Therapeutics PLC | 01 Jul 2021 | 1 | $0 | 4 | Director | 02 Jul 2021, 17:02 |
| /report/000089924321018665-noble-james-2021-05-05 | GW PHARMACEUTICALS PLC | 05 May 2021 | 9 | $0 | 4 | Director | 07 May 2021, 16:15 |